Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott to cut price of AIDS drug in Brazil
Abbott said that the agreement would allow the company to reach its objectives of helping Brazil expand patient access to Kaletra while preserving its intellectual property rights. Although
Abbott said that the agreement would allow the company to reach its objectives of helping Brazil expand patient access to Kaletra while preserving its intellectual property rights. Although
However, the New Jersey-based generic drugmaker will have to follow this new course of action without its chief executive. The company reported the resignation of its interim CEO,
The subject of the agreement is a technology developed at the Gallo Center and at the University of California San Francisco by Dr Jennifer Whistler and Dr Mark
Greenwich owns exclusive license rights to two anticancer agents – sodium stibogluconate (SSG) and triciribine (TCN-P). According to VioQuest, both treatments are attractive compounds for development, given the
MedicAlert’s Health Enhancement System is designed to help patients keep track of their health. It uses voice and text prompts to guide patients through a three minute procedure
In consideration for Vernalis acquiring the entire issued share capital of Ionix, Vernalis will issue to Ionix’s shareholders approximately 9% of the enlarged issued share capital of Vernalis.
The results of a phase III safety and efficacy study of Bio-E-Gel (bioidentical estradiol transdermal gel) for the treatment of moderate-to-severe hot flashes in menopausal women indicate the
The study evaluated Heartzyme, the new systemic oral enzyme, in a small group of participants. Researchers measured C-reactive protein levels as an indication of the presence of inflammation.
The new formulation, called Pennsaid Plus allows the main ingredient, diclofenac, to reach its target faster. The company anticipates that it will take three to five years to
The therapy, known as Prostvac-vf, is designed to stimulate the patient’s own immune system to seek out and destroy malignant cells expressing prostate-specific antigen (PSA), a substance often